

CITATION REPORT

List of articles citing

Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial

DOI: 10.1136/annrheumdis-2013-203497

Annals of the Rheumatic Diseases, 2014, 73, 1954-61.

Source: <https://exaly.com/paper-pdf/59565271/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
37	Rheumatoid arthritis: role for infliximab uncertain as targeted DMARD combinations achieve effective disease control. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 566	8.1	
36	Early start and stop of biologics: has the time come?. <i>BMC Medicine</i> , 2014 , 12, 25	11.4	20
35	Treat to target for rheumatoid arthritis in 2014--time tested triple therapy or logical biologics?. <i>International Journal of Rheumatic Diseases</i> , 2014 , 17, 1-3	2.3	11
34	A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. <i>Rheumatology International</i> , 2015 , 35, 1837-49	3.6	16
33	Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial. <i>Scandinavian Journal of Rheumatology</i> , 2015 , 44, 449-55	1.9	13
32	Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1094-101	2.4	35
31	Initial high-dose prednisolone combination therapy using COBRA and COBRA-light in early rheumatoid arthritis. <i>NeuroImmunoModulation</i> , 2015 , 22, 51-6	2.5	1
30	Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial. <i>Arthritis Care and Research</i> , 2016 , 68, 1758-1766	4.7	6
29	Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). <i>The Cochrane Library</i> , 2016 , 11, CD012437	5.2	18
28	Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996-98 and 2006-09. <i>Scandinavian Journal of Rheumatology</i> , 2016 , 45, 371-8	1.9	10
27	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2017 , 3, CD012591	5.2	29
26	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2017 , 5, CD012657	5.2	33
25	[New options for the practice : Update S1/S2 guidelines on rheumatoid arthritis?]. <i>Zeitschrift Fur Rheumatologie</i> , 2017 , 76, 125-132	1.9	
24	A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. <i>Arthritis and Rheumatology</i> , 2017 , 69, 953-963	9.5	22
23	Stratégie de prise en charge de la polyarthrite rhumatoïde : traitement précoce et traitement ciblé. <i>Revue Du Rhumatisme Monographies</i> , 2017 , 84, 377-381	0	1
22	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. <i>Rheumatology</i> , 2017 , 56, 1586-1596	3.9	10
21	Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. <i>PLoS ONE</i> , 2017 , 12, e0183294	3.7	20

20	Treat-to-Target in Autoimmune Hepatitis: How Far To Go?. <i>Journal of AIDS & Clinical Research</i> , 2017 , 8,	1	
19	Evaluation of work disability in Japanese patients with rheumatoid arthritis: from the TOMORROW study. <i>Clinical Rheumatology</i> , 2018 , 37, 1763-1771	3.9	4
18	Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis: systematic review and meta-analysis. <i>Rheumatology</i> , 2018 , 57, 49-58	3.9	30
17	Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 111-118	2.4	33
16	A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference. <i>Patient Preference and Adherence</i> , 2018 , 12, 375-397	2.4	5
15	Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF- κ B and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two yearsS treatment for Japanese rheumatoid arthritis patients. <i>Modern Rheumatology</i> , 2019 , 29, 418-429	3.3	12
14	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019 , 19, 537-549	2.2	10
13	Predictors of sick leave and improved worker productivity after 52 weeks of intensive treatment in patients with early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2019 , 48, 271-278	1.9	3
12	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. <i>Advances in Therapy</i> , 2019 , 36, 721-745	4.1	1
11	Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial. <i>Arthritis Care and Research</i> , 2019 , 71, 1450-1458	4.7	3
10	Diagnostic test accuracy of magnetic resonance imaging and ultrasound for detecting bone erosion in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2020 , 39, 1283-1293	3.9	3
9	Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study. <i>Journal of Rheumatology</i> , 2020 , 47, 1160-1164	4.1	9
8	First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study. <i>BMC Rheumatology</i> , 2020 , 4, 34	2.9	1
7	Treatment strategies are more important than drugs in the management of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2020 , 39, 1363-1368	3.9	22
6	Pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab. <i>Scandinavian Journal of Rheumatology</i> , 2021 , 1-6	1.9	2
5	The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2017 , 21, 1-258	4.4	27
4	Is non-biological treatment of rheumatoid arthritis as good as biologics?. <i>World Journal of Orthopedics</i> , 2015 , 6, 278-83	2.2	9
3	First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: A nationwide register-based study..		

2 First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: A nationwide register-based study..

1 Work Ability and Quality of Life in Patients with Rheumatoid Arthritis. **2022**, 19, 13260

○